Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 95   

Articles published

SLXP 159.83 -4.40 (-2.68%)
price chart
Salix Pharmaceuticals, Ltd. Set To Be Acquired By Allergan, Inc.
Allergan, Inc. (NYSE: AGN) is set to acquire Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) in a deal probably worth more than $10 billion, according to Dow Jones Newswires.
Allergan Said to Revive Discussions to Buy Salix Pharmaceuticals  Businessweek
Allergan close to deal with Salix to fend off hostile takeover: report  Financial Post
Related articles »  
Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock
... Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States.
Related articles »  
Pharma Stocks in the News: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) said its Santarus Pharmaceuticals unit and the University of Missouri have reached a settlement in a patent infringement case with Par Pharmaceutical.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)'s Xifaxan 550 sNDA Under Review ...
Albany, New York (09/22/2014) - Supplemental new drug application (sNDA) for Xifaxan 550 of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) has been accepted by FDA for review. The company has high hopes from this drug as it can be utilized to cure ...
News Recap: Incontact Inc (SAAS), Salix Pharmaceuticals, Ltd. (SLXP), Anacor ...  Techsonian (press release)
Related articles »  
Why Salix Pharmaceuticals (SLXP) Stock Is Higher Today
NEW YORK (TheStreet) -- Shares of Salix Pharmaceuticals Ltd. (SLXP) are up 1.37% to $158 in pre-market trade as some of the top 20 investors are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals, and are pressing Salix to ...
Top Salix shareholders not on board with Cosmo deal  Seeking Alpha (registration)
Exclusive: Top investors push Salix to abandon Cosmo deal - sources  Reuters
Related articles »  
Cipla Ltd grants Salix Pharmaceuticals Ltd rights for Rifaximin
MUMBAI: Indian drugmaker Cipla Ltd has agreed to grant US-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.
Credit Suisse Sees Downside In Shares Of Salix Pharmaceuticals, Ltd.
Analysts at Credit Suisse initiated coverage on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) with an Underperform rating and $139 price target Friday.
Salix Pharmaceuticals Receives New Coverage from Analysts at Credit Suisse ...  sleekmoney
Related articles »  
Salix Pharmaceuticals Larger Than S&P 500 Component Expedia
... capitalization (factoring in those share counts) creates a true ´┐Żapples-to-apples´┐Ż comparison of the value of two stocks. In the case of Salix Pharmaceuticals Ltd (NASD: SLXP), the market cap is now $10.04B, versus Expedia Inc (NASD: EXPE) at $10.00B.
Related articles »  
Salix Signs Deal With Lupin
Salix Pharmaceuticals, Ltd. (SLXP) has entered into an agreement with India-based pharmaceutical Lupin Limited; granting the company commercialization rights for two of its gastrointestinal drugs, Zaxine and Relistor, in Canada.
Lupin To Market Salix Pharma Products In Canada  RTT News
CORRECTED-India's Lupin in deal to market US firm Salix's drugs in ...  Reuters
Related articles »  
Credit Suisse Initiates Coverage on Salix Pharmaceuticals (SLXP)
Salix Pharmaceuticals, Ltd. logo Equities research analysts at Credit Suisse began coverage on shares of Salix Pharmaceuticals (NASDAQ:SLXP) in a research note issued to investors on Friday, TheFlyOnTheWall.
Related articles »